Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
Clinical role
Concurrent detection and characterization aid
Images and patients
Ultrasound · Obstetric/Fetal
Key limitation
Keep in mind: Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Obstetric/Fetal Input: Fetal ultrasound images acquired at gestational age 11-41 weeks, with finding-specific trimester and view restrictions.
Who uses it?Intended users: Interpreting physicians, including maternal-fetal medicine specialists, OB/GYNs and radiologists.
What does the software produce?Output: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
What is its most important limitation?Key limitation: Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.
Clinical takeaway. Clinical role: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
Evidence takeaway. Evidence from the reviewed source record: Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.
Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.
Exact FDA submission
Checked 2026-09-05
Public summary does not report a single test sample total. The averages should not be interpreted as per-abnormality performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.
FDA source
Exact FDA submission
Checked 2026-09-05
Public summary does not report a single test sample total. The averages should not be interpreted as per-abnormality performance.
Average for the K261519 integration configuration in standalone bench testing of the specified fetal findings under predicate protocol/dataset criteria. Sample total is not stated in the summary; no prospective screening-population sensitivity is inferred.
Average for the K261519 integration configuration in standalone bench testing of the specified fetal findings under predicate protocol/dataset criteria. Sample total is not stated in the summary; not a per-finding or real-world prevalence-adjusted estimate.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DesignBench comparison using predicate protocol and dataset criteria after conversion to embedded C++
PopulationFetal ultrasound views for the specified abnormal findings within labeled gestational-age restrictions
Scopeexact submission
Tested versionSonio Suspect K261519 integration configuration compared with cloud configuration
IndependenceSponsor or vendor study
K261519
Algorithms, weights and thresholds were unchanged. Public summary provides average sensitivity/specificity and confidence intervals, but not a sample total or prospective clinical outcomes.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Fetal ultrasound images acquired at gestational age 11-41 weeks, with finding-specific trimester and view restrictions.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The third-party manufacturer is responsible for user-interface integration and final system validation; the integrated configuration must meet minimum hardware requirements.
Scope: Exact FDA submission. The summary does not provide a procurement-ready list of compatible machine models or complete hardware specifications.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: K261519 adds a C++ integration configuration for third-party ultrasound systems to the existing Python web-based/cloud configuration, with the algorithm logic, weights and thresholds unchanged.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
K261519 adds a C++ integration configuration for third-party ultrasound systems to the existing Python web-based/cloud configuration, with the algorithm logic, weights and thresholds unchanged.
The third-party manufacturer is responsible for user-interface integration and final system validation; the integrated configuration must meet minimum hardware requirements.
Exact FDA submission
Checked 2026-09-05
The summary does not provide a procurement-ready list of compatible machine models or complete hardware specifications.
Sonio's security page states HIPAA and GDPR compliance, HDS-certified cloud providers, SOC 2 Type 2 compliance, encryption at rest and in transit, a web application firewall with intrusion detection, and isolated regional deployments. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored candidate metadata contained no PubMed or trial records for this ID; this is not a claim that no literature exists. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor announcement, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
No OEM integration license or site price is established by the reviewed announcement or summary.
Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission
OEM, per-device and per-examination commercial terms require a quote.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Sonio Suspect reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
OEM-specific operator training, escalation and competency materials were not established.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Completed real-world integration testing and ongoing clinical monitoring commitments were not verified.
Authorized purpose: Butterfly Gestational Age Tool estimates gestational age for a singleton intrauterine pregnancy presumed to be 16 to 37 weeks within the labeled Butterfly ultrasound workflow; qualified professionals must review the output.
Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Authorized purpose: Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.
Authorized purpose: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.